BCLPX
Price
$8.67
Change
-$0.03 (-0.34%)
Updated
Jun 2 closing price
Net Assets
4.78B
EMAAX
Price
$18.20
Change
+$0.03 (+0.17%)
Updated
Jun 2 closing price
Net Assets
59.72M
Interact to see
Advertisement

BCLPX vs EMAAX

Header iconBCLPX vs EMAAX Comparison
Open Charts BCLPX vs EMAAXBanner chart's image
BCLPX vs EMAAX Comparison Chart in %
View a ticker or compare two or three
VS
BCLPX vs. EMAAX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCLPX is a Buy and EMAAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
BCLPX has more cash in the bank: 4.78B vs. EMAAX (59.7M). BCLPX pays higher dividends than EMAAX: BCLPX (3.07) vs EMAAX (1.08). BCLPX was incepted earlier than EMAAX: BCLPX (18 years) vs EMAAX (25 years). BCLPX (2.36) is less costly to investors than EMAAX (1.87). EMAAX is a more actively managed with annual turnover of: 100.00 vs. BCLPX (81.00). BCLPX (1000) and EMAAX (1000) have matching initial minimum investment requirements. EMAAX annual gain was more profitable for investors over the last year : 20.68 vs. BCLPX (3.88). EMAAX return over 5 years is better than : 13.31 vs. BCLPX (6.02).
BCLPXEMAAXBCLPX / EMAAX
Total Expense Ratio2.271.87121%
Annual Report Gross Expense Ratio2.361.87126%
Fund Existence18 years25 years-
Gain YTD1.2817.32417%
Front LoadN/A6%-
Min. Initial Investment10001000100%
Min. Initial Investment IRAN/AN/A-
Net Assets4.78B59.7M8,007%
Annual Yield % from dividends3.071.08284%
Returns for 1 year3.8820.6819%
Returns for 3 years14.8337.1740%
Returns for 5 years6.0213.3145%
Returns for 10 years20.6037.5355%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MPB32.870.76
+2.37%
Mid Penn Bancorp
CPRX31.27N/A
N/A
Catalyst Pharmaceuticals
BCDA0.90-0.03
-2.71%
BioCardia Inc.
TEAM109.10-6.85
-5.91%
Atlassian Corp
GALT2.42-0.19
-7.28%
Galectin Therapeutics